Peak Bggradded this to Biotech InvestingMetformin European advisory group backs AstraZeneca combo pill for T2DSeeking Alpha - Douglas W. House The European Medicine Agency's advisory group CHMP has adopted a positive opinion recommending approval of AstraZeneca's (NYSE:AZN) Qtrilmet (850 mg …
Seeking AlphaInvesting Drug makers up after McConnell thumbs down on Pelosi price pricing planSeeking Alpha - Douglas W. House Members of Big Biopharma are in the green as investors exhale after Senate Majority Leader Mitch McConnell (R-KY) warned House Speaker Nancy Pelosi …
Sweden Stockholm stock market climbs to all-time highthelocal.se - TT/The Local Stockholm's OMXS index rose 0.04 on Thursday and closed at 630.4, a historically high level. It broke a previous record set in April. Anglo-Swedish …
FDA Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updatesyahoo.com - Kinjel Shah The FDA was fairly active this week, granting approval for expanded use of Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda and J&J’s JNJ new …
Seeking AlphaInvesting European advisory group backs Astellas Pharma's gilteritinib for certain type of leukemiaSeeking Alpha - Douglas W. House The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Astellas Pharma Europe B.V.'s …
MarketWatchadded this to MarketsStock Markets U.K. stocks snap three-day losing runMarketWatch - By Steve Goldstein U.K. stocks closed higher Thursday to end a three-day losing run, led higher by more defensive plays. The FTSE 100 UKX, -0.17% rose 0.58% to 7356.42, …
Investor's Business Dailyadded this to Financial & Business NewsBusiness Stock Upgrades: Roche Shows Rising Relative Strengthinvestors.com - INVESTOR'S BUSINESS DAILY Roche (RHHBY) had its Relative Strength (RS) Rating upgraded from 64 to 72 Wednesday -- a welcome improvement, but still shy of the 80 or better …
Peak Bggradded this to Biotech InvestingChina Ironwood Pharma and Astrazeneca amend Linzess deal in ChinaSeeking Alpha - Mamta Mayani Ironwood Pharmaceuticals (NASDAQ:IRWD) has amended its collaboration agreement with AstraZeneca (NYSE:AZN) for the development and commercialization …
Personal Finance (UK) Why I’d buy this dividend-growing share alongside AstraZenecafool.co.uk - Kevin Godbold Pharmaceutical giant AstraZeneca looks like it’s moving into a period of profit growth after several years of contracting earnings. New products and …
Icon version of the Flipboard logoBusiness (UK)Graziano enters senior recruitment ring with a knockout tech proposition | Business Weekly | Technology News | Business |businessweekly.co.uk - www.businessweekly.co.uk Former AstraZeneca talent spotter Joe Graziano has started his own executive search business in Cambridge focusing exclusively on high …
Medicine A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Credmedscape.com - www.medscape.com PHILADELPHIA — Once again, the antidiabetic drug dapagliflozin (Farxiga, AstraZeneca) showed that the term "antidiabetic drug" doesn't really capture …
Seeking AlphaOncology Revisiting Pieris PharmaceuticalsSeeking Alpha Every man has inside himself a parasitic being who is acting not at all to his advantage.”― William S. Burroughs Today we revisit Pieris …
Seeking Alphaadded this to Breaking NewsInvesting New Chair of Board of Directors at ZymeworksSeeking Alpha - Mamta Mayani Zymeworks (NYSE:ZYME) appoints Lota Zoth as its Chair of the Board of Directors. She succeeds Nick Bedford, who has retired from his functions. Ms. …
ReutersHeart Failure AstraZeneca diabetes drug granted fast track status for heart...ReutersFILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, England, May 19, 2014. REUTERS/Phil Noble/File Photo (Reuters) - AstraZeneca’s diabetes drug, Farxiga, has been granted fast track designation
Seeking AlphaInvesting AstraZeneca's Farxiga Fast Track'd for CV benefit claimSeeking Alpha - Douglas W. House The FDA designates AstraZeneca's (NYSE:AZN) Farxiga (dapagliflozin) for Fast Track review for reducing the risk of cardiovascular (CV) death, or the …
ReutersStocks UPDATE 2-UK Stocks-Factors to watch on Sept 16Reuters - Reuters EditorialSept 16 (Reuters) - Britain’s FTSE 100 index is seen opening 30 points lower at 7,338 on Monday, according to financial bookmakers, with futures down 0.3% ahead of cash market open. * ASTRAZENECA: AstraZeneca
Peak Bggradded this to Biotech InvestingInvesting AstraZeneca's Latest Lung Cancer Test Data Makes It A Force To Be Reckoned WithSeeking Alpha - Terry Chrisomalis AstraZeneca (AZN) recently reported a highly positive outcome in treating patients with front-line extensive-stage small cell lung cancer (SCLC) using …
Asthma Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Useyahoo.com - Zacks Equity Research GlaxoSmithKline plc GSK announced that the FDA has granted approval to Nucala as an add-on treatment for severe eosinophilic asthma in the pediatric …
Investing.com UKadded this to UK NewsFTSE FTSE 100 slips as pound recovers, Diageo slides By Reutersinvesting.com - Reuters (Reuters) - Britain's main index edged lower on Friday as exporter stocks took a hit from a rise by the pound to near two-month highs, while energy …
Chemotherapy Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Othersyahoo.com - Kinjel Shah This week, the FDA granted approval to Glaxo’s GSK asthma drug, Nucala for pediatric use. Meanwhile, Pfizer PFE, Allergan AGN and Roche RHHBY …
Seeking AlphaPharma Innate Pharma SA (IPHYF) CEO Mondher Mahjoubi on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha - SA Transcripts Innate Pharma SA (OTCPK:IPHYF) Q2 2019 Results Conference Call September 13, 2019 8:00 AM ET Good afternoon, ladies and gentlemen, and welcome to the …
Icon version of the Flipboard logoEducationAstraZeneca, Learning Undefeated and Discovery Education Launch New Generation Health Program to Encourage Healthy Livingcsrwire.com - Web Design & Development by Fuzz Productions & Singlebrook Silver Spring, Md., Sep. 12 /CSRwire/ - AstraZeneca, Learning Undefeated and Discovery Education, the leading provider of standards-aligned digital …
Cancer 4 Big Drugmakers Boasting Impressive Oncology Pipelinesyahoo.com - Kinjel Shah There has been a significant uptick in demand for cancer drugs and subsequent growth of the cancer research market owing to the widespread occurrence …
FTSE Have £2,000 to invest in the FTSE 100? I’d buy these 2 growth stocks in an ISA todayfool.co.uk - Peter Stephens With the global economy’s outlook highly uncertain at present, FTSE 100 stocks that offer relatively consistent growth could become increasingly …
Bristol-Myers Squibb Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefityahoo.com - Zacks Equity Research Bristol-Myers Squibb Company BMY announced long-term pooled efficacy and safety results from the phase III CheckMate-017 and CheckMate-057 studies in …
Icon version of the Flipboard logoBusiness (UK)Cambridge spearheads £200m genome sequencing revolution | Business Weekly | Technology News | Business news | Cambridge thebusinessweekly.co.uk - www.businessweekly.co.uk Cambridge genetic research world-leaders the Wellcome Trust Sanger Centre and Illumina are spearheading a blockbusting £200 million genomics …
adamadded this to HealthMicrosoft Microsoft and AstraZeneca join forces on artificial intelligence for healthcare - Microsoft News Centre Europemicrosoft.com - Esat Dedezade Microsoft and AstraZeneca have announced an artificial intelligence (AI) collaboration for the benefit of healthcare patients, by introducing the AI …
Bloombergadded this to EconomicsEconomics China Spares Cancer Drugs From Trade War in Relief to Big PharmaBloomberg China is not letting its ongoing trade war with the U.S. get in the way of health care reform. Twelve cancer drugs are among a short list of U.S. …
Seeking Alphaadded this to IPOsInvesting Viela Bio IPO: At Phase 3 Of Development With Positive ResultsSeeking Alpha - Bilbao Asset Management With product candidates acquired from AstraZeneca (AZN) and MedImmune, Viela Bio (VIE) is clinical-stage biotechnology to be followed carefully. …
Bloombergadded this to Bloomberg TelevisionChina AstraZeneca's Executive VP, Leon Wang, Sees Upside, As China's Government Speeds Up Drug ApprovalBloomberg AstraZeneca PLC is betting on sales of its new drug to outweigh that of off-patient ones in China over the next five years amid Chinese regulator's …
